Combination of secretin and fluvastatin ameliorates the polyuria associated with X-linked nephrogenic diabetes insipidus in mice

Kidney International

Volumn 86, Issue 1, 2014, Pages 127-138

  Procino, Giuseppe ^a,b   Milano, Serena ^a   Carmosino, Monica ^a   Barbieri, Claudia ^a   Nicoletti, Maria C ^a   H Li, Jian ^c   Wess, Jürgen ^c   Svelto, Maria ^a,b  

^a UNIVERSITY OF BARI   (Italy)

^b Centro di Eccellenza di Genomica in Campo Biomedico ed Agrario (CEGBA)   (Italy)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

cell and transport physiology; collecting ducts; diabetes insipidus; statins; vasopressin; water channels

Indexed keywords

AQUAPORIN 2; CYCLIC AMP; FLUINDOSTATIN; SECRETIN; VASOPRESSIN V2 RECEPTOR; AQP2 PROTEIN, MOUSE; G PROTEIN COUPLED RECEPTOR; HORMONE RECEPTOR; INDOLE DERIVATIVE; MESSENGER RNA; MONOUNSATURATED FATTY ACID; SECRETIN RECEPTOR; VASOPRESSIN RECEPTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOSOL; DISEASE ASSOCIATION; DIURESIS; DRUG EFFECT; DRUG MECHANISM; EXOCYTOSIS; FLUID INTAKE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; KIDNEY COLLECTING TUBULE; MALE; MOUSE; NEPHROGENIC DIABETES INSIPIDUS; NONHUMAN; OUTCOME ASSESSMENT; POLYURIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; SINGLE DRUG DOSE; URINE OSMOLALITY; URINE VOLUME; WILD TYPE; X CHROMOSOME LINKED DISORDER; ANIMAL; C57BL MOUSE; COMPLICATION; DEFICIENCY; DIABETES INSIPIDUS, NEPHROGENIC; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; METABOLISM; MUTANT MOUSE STRAIN; PATHOPHYSIOLOGY;

ANIMALS; AQUAPORIN 2; CYCLIC AMP; DIABETES INSIPIDUS, NEPHROGENIC; DISEASE MODELS, ANIMAL; EXOCYTOSIS; FATTY ACIDS, MONOUNSATURATED; GENE EXPRESSION; HUMANS; INDOLES; KIDNEY TUBULES, COLLECTING; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; POLYURIA; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, VASOPRESSIN; RNA, MESSENGER; SECRETIN;

EID: 84903794772     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.10     Document Type: Article

References (42)

1. Bichet DG. V2R mutations and nephrogenic diabetes insipidus. Prog Mol Biol Transl Sci 2009; 89: 15-29.
2. Robben JH, Knoers NV, Deen PM. Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus. Am J Physiol Renal Physiol 2006; 291: F257-F270. (Pubitemid 44148115)
3. Wesche D, Deen PM, Knoers NV. Congenital nephrogenic diabetes insipidus: The current state of affairs. Pediatr Nephrol 2012; 27: 2183-2204.
4. Boone M, Deen PM. Physiology and pathophysiology of the vasopressinregulated renal water reabsorption. Pflugers Arch 2008; 456: 1005-1024.
5. Hasler U, Leroy V, Martin PY et al. Aquaporin-2 abundance in the renal collecting duct: New insights from cultured cell models. Am J Physiol Renal Physiol 2009; 297: F10-F18.
6. Knepper MA, Inoue T. Regulation of aquaporin-2 water channel trafficking by vasopressin. Curr Opin Cell Biol 1997; 9: 560-564. (Pubitemid 27354767)
7. Moeller HB, Fenton RA. Cell biology of vasopressin-regulated aquaporin-2 trafficking. Pflugers Arch 2012; 464: 133-144.
8. Nedvetsky PI, Tamma G, Beulshausen S et al. Regulation of aquaporin-2 trafficking. Handb Exp Pharmacol 2009; 133-157.
9. Tamma G, Procino G, Svelto M et al. Cell culture models and animal models for studying the patho-physiological role of renal aquaporins. Cell Mol Life Sci 2012; 69: 1931-1946.
10. Tamma G, Procino G, Strafino A et al. Hypotonicity induces aquaporin-2 internalization and cytosol-To-membrane translocation of ICln in renal cells. Endocrinology 2007; 148: 1118-1130.
11. Bouley R, Hawthorn G, Russo LM et al. Aquaporin 2 (AQP2) and vasopressin type 2 receptor (V2R) endocytosis in kidney epithelial cells: AQP2 is located in 'endocytosis-resistant' membrane domains after vasopressin treatment. Biol Cell 2006; 98: 215-232.
12. Yasui M, Zelenin SM, Celsi G et al. Adenylate cyclase-coupled vasopressin receptor activates AQP2 promoter via a dual effect on CRE and AP1 elements. Am J Physiol 1997; 272: F443-F450.
13. Deen PM, van Aubel RA, van Lieburg AF et al. Urinary content of aquaporin 1 and 2 in nephrogenic diabetes insipidus. J Am Soc Nephrol 1996; 7: 836-841. (Pubitemid 27465976)
14. Kanno K, Sasaki S, Hirata Y et al. Urinary excretion of aquaporin-2 in patients with diabetes insipidus. N Engl J Med 1995; 332: 1540-1545.
15. Li JH, Chou CL, Li B et al. A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus. J Clin Invest 2009; 119: 3115-3126.
16. Promeneur D, Kwon TH, Frokiaer J et al. Vasopressin V(2)- receptordependent regulation of AQP2 expression in Brattleboro rats. Am J Physiol Renal Physiol 2000; 279: F370-F382.
17. Knoers N, Monnens LA. Nephrogenic diabetes insipidus: Clinical symptoms, pathogenesis, genetics and treatment. Pediatr Nephrol 1992; 6: 476-482.
18. Knoers NV, Deen PM. Molecular and cellular defects in nephrogenic diabetes insipidus. Pediatr Nephrol 2001; 16: 1146-1152. (Pubitemid 34026741)
19. Bouley R, Breton S, Sun T et al. Nitric oxide and atrial natriuretic factor stimulate cGMP-dependent membrane insertion of aquaporin 2 in renal epithelial cells. J Clin Invest 2000; 106: 1115-1126.
20. Bouley R, Hasler U, Lu HA et al. Bypassing vasopressin receptor signaling pathways in nephrogenic diabetes insipidus. Semin Nephrol 2008; 28: 266-278. (Pubitemid 351756522)
21. Bouley R, Lu HA, Nunes P et al. Calcitonin has a vasopressin-like effect on aquaporin-2 trafficking and urinary concentration. J Am Soc Nephrol 2011; 22: 59-72.
22. Li W, Zhang Y, Bouley R et al. Simvastatin enhances aquaporin-2 surface expression and urinary concentration in vasopressin-deficient Brattleboro rats through modulation of Rho GTPase. Am J Physiol Renal Physiol 2011; 301: F309-F318.
23. Olesen ET, Rutzler MR, Moeller HB et al. Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus. Proc Natl Acad Sci USA 2011; 108: 12949-12954.
24. Procino G, Barbieri C, Carmosino M et al. Fluvastatin modulates renal water reabsorption in vivo through increased AQP2 availability at the apical plasma membrane of collecting duct cells. Pflugers Arch 2011; 462: 753-766.
25. Russo LM, McKee M, Brown D. Methyl-beta-cyclodextrin induces vasopressin-independent apical accumulation of aquaporin-2 in the isolated, perfused rat kidney. Am J Physiol Renal Physiol 2006; 291: F246-F253. (Pubitemid 43945955)
26. Los EL, Deen PM, Robben JH. Potential of nonpeptide (ant)agonists to rescue vasopressin V2 receptor mutants for the treatment of X-linked nephrogenic diabetes insipidus. J Neuroendocrinol 2010; 22: 393-399.
27. Jean-Alphonse F, Perkovska S, Frantz MC et al. Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus. J Am Soc Nephrol 2009; 20: 2190-2203.
28. Robben JH, Kortenoeven ML, Sze M et al. Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists. Proc Natl Acad Sci USA 2009; 106: 12195-12200.
29. Chu JY, Yung WH, Chow BK. Secretin: A pleiotrophic hormone. Ann N Y Acad Sci 2006; 1070: 27-50. (Pubitemid 44126624)
30. Trimble ER, Bruzzone R, Biden TJ et al. Secretin stimulates cyclic AMP and inositol trisphosphate production in rat pancreatic acinar tissue by two fully independent mechanisms. Proc Natl Acad Sci USA 1987; 84: 3146-3150. (Pubitemid 17085361)
31. Chu JY, Chung SC, Lam AK et al. Phenotypes developed in secretin receptor-null mice indicated a role for secretin in regulating renal water reabsorption. Mol Cell Biol 2007; 27: 2499-2511. (Pubitemid 46581342)
32. Charlton CG, Quirion R, Handelmann GE et al. Secretin receptors in the rat kidney: Adenylate cyclase activation and renal effects. Peptides 1986; 7: 865-871. (Pubitemid 17182355)
33. Velmurugan S, Brunton PJ, Leng G et al. Circulating secretin activates supraoptic nucleus oxytocin and vasopressin neurons via noradrenergic pathways in the rat. Endocrinology 2010; 151: 2681-2688.
34. Glaser S, Lam IP, Franchitto A et al. Knockout of secretin receptor reduces large cholangiocyte hyperplasia in mice with extrahepatic cholestasis induced by bile duct ligation. Hepatology 2010; 52: 204-214.
35. Wang X, Ye H, Ward CJ et al. Insignificant effect of secretin in rodent models of polycystic kidney and liver disease. Am J Physiol Renal Physiol 2012; 303: F1089-F1098.
36. Holtmann MH, Roettger BF, Pinon DI et al. Role of receptor phosphorylation in desensitization and internalization of the secretin receptor. J Biol Chem 1996; 271: 23566-23571. (Pubitemid 26314809)
37. Ozcelebi F, Holtmann MH, Rentsch RU et al. Agonist-stimulated phosphorylation of the carboxyl-Terminal tail of the secretin receptor. Mol Pharmacol 1995; 48: 818-824.
38. Shetzline MA, Premont RT, Walker JK et al. A role for receptor kinases in the regulation of class II G protein-coupled receptors. Phosphorylation and desensitization of the secretin receptor. J Biol Chem 1998; 273: 6756-6762. (Pubitemid 28160337)
39. Kortenoeven ML, Trimpert C, van den Brand M et al. In mpkCCD cells, long-Term regulation of aquaporin-2 by vasopressin occurs independent of protein kinase A and CREB but may involve Epac. Am J Physiol Renal Physiol 2012; 302: F1395-F1401.
40. Ares GR, Caceres PS, Ortiz PA. Molecular regulation of NKCC2 in the thick ascending limb. Am J Physiol Renal Physiol 2011; 301: F1143-F1159.
41. Hardcastle IR, Rowlands MG, Barber AM et al. Inhibition of protein prenylation by metabolites of limonene. Biochem Pharmacol 1999; 57: 801-809. (Pubitemid 29094551)
42. Oppermann M, Mizel D, Kim SM et al. Renal function in mice with targeted disruption of the A isoform of the Na-K-2Cl co-Transporter. J Am Soc Nephrol 2007; 18: 440-448. (Pubitemid 46193310)